Systemic Lupus Erythematosus Clinical Trials

124 recruiting

Systemic Lupus Erythematosus Trials at a Glance

185 actively recruiting trials for systemic lupus erythematosus are listed on ClinicalTrialsFinder across 6 cities in 61 countries. The largest study group is Phase 1 with 76 trials, with the heaviest enrollment activity in New York, Beijing, and Beijing. Lead sponsors running systemic lupus erythematosus studies include AstraZeneca, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Browse systemic lupus erythematosus trials by phase

Treatments under study

About Systemic Lupus Erythematosus Clinical Trials

Looking for clinical trials for Systemic Lupus Erythematosus? There are currently 124 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus Erythematosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus Erythematosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 185 trials

Recruiting

Study of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT00001372
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled225 locationsNCT06617325
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting

Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus

Systemic Lupus ErythematosusPhysiopathology
University Hospital, Tours50 enrolled1 locationNCT05859191
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled132 locationsNCT07409181
Recruiting
Phase 2

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Eisai Co., Ltd.256 enrolled17 locationsNCT07515014
Recruiting
Phase 1

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

Rheumatoid ArthritisSclerodermaSystemic Lupus Erythematosus
Shenzhen MagicRNA Biotechnology Co., Ltd30 enrolled1 locationNCT06801119
Recruiting
Phase 1

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Systemic Lupus Erythematosus
GlaxoSmithKline142 enrolled27 locationsNCT06576271
Recruiting

The Anifrolumab PRIM Program

Systemic Lupus Erythematosus
AstraZeneca240 enrolled1 locationNCT06795893
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled35 locationsNCT06916806
Recruiting
Phase 2

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

Active Systemic Lupus Erythematosus
InventisBio Co., Ltd120 enrolled1 locationNCT07311200
Recruiting

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

Systemic Lupus ErythematosusAntiphospholipid Syndrome
Hospital for Special Surgery, New York700 enrolled10 locationsNCT00198068
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

Systemic Lupus Erythematosus (SLE)
Shanghai Jiao Tong University School of Medicine60 enrolled1 locationNCT07425730
Recruiting

Anifrolumab Malignancy and Serious Infections Study

Systemic Lupus Erythematosus
AstraZeneca3,195 enrolled4 locationsNCT07000110
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07332481
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Systemic Lupus Erythematosus (SLE)
AstraZeneca200 enrolled6 locationsNCT06314282
Recruiting
Phase 1

Alnuctamab for Refractory SLE (LATTE Study)

Systemic Lupus Erythematosus
Icahn School of Medicine at Mount Sinai21 enrolled1 locationNCT07219563